These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 32454143)

  • 1. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
    Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
    Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
    Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
    Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.
    Lee YG; Marks I; Srinivasarao M; Kanduluru AK; Mahalingam SM; Liu X; Chu H; Low PS
    Cancer Res; 2019 Jan; 79(2):387-396. PubMed ID: 30482775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
    Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
    Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
    Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
    Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
    Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
    Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
    Front Immunol; 2020; 11():99. PubMed ID: 32117253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
    Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
    Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
    PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
    Tang XY; Ding YS; Zhou T; Wang X; Yang Y
    Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
    Shen C; Zhang Z; Zhang Y
    Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.